Username  
Password  
  
increase font sizeEnlarge text size

 

A knowledge-based enterprise since formation, Interpath has invested heavily in research and development of their joint nutraceutical products, which have resulted in ground breaking results in the research of cellular and tissue inflammation including degenerative joint disease (DJD).

 

Interpath has utilised the latest molecular and cellular biology techniques and technologies, with in-vivo and in-vitro studies providing unequivocal understanding of the science behind their signature products.   

 

 

Australian research company Interpath achieves highest International recognition for new generation Sashas EQ.
The future has arrived! That was the overwhelming response at the conclusion of Dr Wendy Pearson's presentation at the recent British Equine Veterinarian Association Conference (BEVA) in Liverpool, England. Dr Pearson presented results from a major four year research project funded by Interpath. The project discovered a new botanical joint health -active- and developed an all new joint health product for horses called Sashas EQ.
More News...
Search 

Interpath Global Positioning

 



All Content © 2012 Interpath - Website by CeCC  | Intellectual Property | Sitemap